Bosutinib in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, and hematological safety characterization in the BFORE trial Meeting Abstract
| Authors: | Mauro, M. J.; Gambacorti-Passerini, C.; Deininger, M. W.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; le Coutre, P. D.; Gutiérrez, V. G.; Reilly, L.; Jeynes-Ellis, A.; Crescenzo, R. J.; Uehara, R.; Leip, E.; DeAnnuntis, L.; Bardy-Bouxin, N.; Hochhaus, A.; Brummendorf, T. H.; Cortes, J. E. |
| Abstract Title: | Bosutinib in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, and hematological safety characterization in the BFORE trial |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419404064 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.1620.1620 |
| Notes: | Meeting Abstract: 1620 -- Source: Wos |
